Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort study

Anette Arbjerg Højen, Anders Gorst-rasmussen, Gregory Y.h. Lip, Deirdre A. Lane, Lars Hvilsted Rasmussen, Erik Elgaard Sørensen, Torben Bjerregaard Larsen

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
309 Downloads (Pure)


The mental health prognosis following a venous thromboembolism in youth has not been investigated comprehensively. Using psychotropic drug purchase as a proxy for mental health status, we investigated this issue in a large cohort of young incident venous thromboembolism patients.

Using Danish nationwide administrative registries from the period 1997–2010, we identified 4,132 patients aged 13–33 years with a first-time venous thromboembolism diagnosis and no history of psychotropic drug usage. We sampled comparison cohort of random general population controls, matched individually in a 1:5 ratio based on sex and birth year. Participants were followed in prescription purchase registries for their first psychotropic drug purchase.

Among young venous thromboembolism case cases, the 1-year risk of psychotropic drug purchase was 7.1% (95% confidence interval [CI] 6.3, 7.9) and the 5-year risk 22.1% (95% CI 20.7, 23.5). This was substantially higher than among population controls, with 1- and 5-year risk differences relative to the controls of 4.7% (95% CI 3.9, 5.5), and 10.8% (95% CI 9.4, 12.3), respectively. Adjustment for the effects of recent pregnancy or somatic provocations attenuated risk differences to 4.1% (95% CI 3.5, 5.1) after 1 year and 9.6% (95% CI 8.3, 11.2) after 5 years.

A venous thromboembolism diagnosis in youth is associated with a poorer mental health prognosis: one in five patients are prescribed psychotropic medication within the first 5 year after diagnosis.
Original languageEnglish
JournalThrombosis Research
Early online date24 Jan 2015
Publication statusE-pub ahead of print - 24 Jan 2015


Dive into the research topics of 'Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort study'. Together they form a unique fingerprint.

Cite this